Milestone Alert: Arcutis Completes Enrollment in Phase 2 Study of Roflumilast Cream, 0.05% in Infants With AD
The last subject has been enrolled in the INTEGUMENT-INFANT Phase 2 study of investigational once-daily roflumilast cream, 0.05% (Zoryve, Arcutis) in infants with mild-to-moderate atopic dermatitis (AD).